call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Minimal Residual Disease Testing Market
Inquire Before Buying Request for Sample

Minimal Residual Disease Testing Market

Home Healthcare And Pharmaceutical Minimal Residual Disease Testing Market

Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Test Type (DNA-based Test, RNA-based Test, Immunological Test); By Technology (NGS, PCR, Flow Cytometry, Fluorescence In-situ Hybridization); By Application (Hematological Malignancies, Solid Tumors); By End Use (Hospitals, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published Date: May 2023
  • Report ID: BWC23357
  • Available Format: PDF
  • Page: 400

Report Overview

Growing prevalence of cancer worldwide leading to an increased demand for accurate and reliable diagnostic tests, increasing adoption of precision medicine approaches, and growing trend towards early cancer diagnosis and detection are projected to propel the expansion of global minimal residual disease testing market during the forecast period between 2023 and 2029.

Global Minimal Residual Disease Testing Market - Industry Trends & Forecast Report, 2029

Global minimal residual disease testing market size was estimated at USD 1.54 billion in 2022. During the forecast period between 2023 and 2029, the size of global minimal residual disease testing market is projected to grow at CAGR of 14.6% reaching a value of USD 3.96 billion by 2029. Major growth drivers for global minimal residual disease testing market include rising cancer rates, growing recognition among consumers of the importance of therapy, as well as increased investments in research, and high disposable income in developing nations. Another primary driver of market growth during the forecast period is the escalating prevalence of cancer. According to the World Health Organization, cancer is currently the second most common cause of death worldwide. In 2020, there were 19.3 million reported cases of cancer and 9.96 million deaths related to the disease. The International Agency for Research on Cancer predicts that the number of cancer cases will rise to 21.9 million by 2025 and 24.6 million by 2030. As a result, governments are expected to establish new cancer screening programs to address this surge in cases. Also, the market is expected to experience growth due to increased investments in MRD (minimal residual disease) testing programs. MRD diagnostic and monitoring research is expanding, which is creating demand for these services.

Global Minimal Residual Disease Testing Market

Global Minimal Residual Disease Testing Market – Overview

Global minimal residual disease (MRD) testing market refers to the market for diagnostic tests used to detect the presence of cancer cells in patients who have undergone treatment. MRD testing is a highly sensitive and specific technique that is capable of detecting small amounts of cancer cells that may remain in a patient's body after treatment. The MRD testing market includes products and services such as assays, flow cytometers, and other testing equipment, as well as related services such as sample preparation and analysis. The market caters to healthcare providers, research organizations, and pharmaceutical companies who use MRD testing for disease monitoring, treatment selection, and clinical trial endpoints.

Global Minimal Residual Disease Testing Market

Growth Drivers

Growing Focus on Early Cancer Diagnosis and Detection

The growing trend towards early cancer diagnosis and detection refers to the increasing emphasis on detecting cancer in its preliminary stages, before symptoms appear or the disease has advanced. Early diagnosis can lead to better treatment outcomes and increased chances of survival. This trend is driven by several factors, including public awareness campaigns, advances in screening technologies, and a greater emphasis on preventive healthcare. As a result, there is a greater demand for diagnostic tests that can detect cancer in its initial stages, including MRD testing.

Restraints

Challenges in Applying MRD Tests due to Stringent and Intricate Regulations

The application of MRD tests is governed by stringent and intricate regulations, similar to other diagnostic and treatment procedures. Various concerns regarding the effectiveness and appropriateness of these tests arise, depending on the type of test being used. For instance, while multiparameter flow cytometry tests can be complicated to interpret, they may not identify certain cytogenetic traits. Consequently, the combination of rigorous rules and limitations of MRD tests impedes the development and advancement of the minimal residual disease testing industry.

Impact of COVID-19 on Global Minimal Residual Disease Testing Market

COVID-19 adversely affected the global minimal residual disease (MRD) testing market. With the focus on the virus and the strain on healthcare systems, the demand for MRD testing was affected. The restrictions imposed due to the pandemic, such as social distancing and lockdown measures, also resulted in delays or cancellations of elective procedures, including MRD testing. Also, the disruption in the supply chain and manufacturing processes led to a shortage of necessary components and instruments required for testing. The uncertain economic conditions and reduced funding for research and development may further impede the growth of the MRD testing market in the near future.

Global Minimal Residual Disease Testing Market

Segmental Coverage

Global Minimal Residual Disease Testing Market – By Test Type

Based on test type, the global minimal residual disease testing market is divided into DNA-based Test, RNA-based Test, and Immunological Test. The DNA-based tests segment held the highest share of the MRD testing market due to their high sensitivity and specificity in detecting cancer cells. However, the RNA-based tests segment was expected to grow at the fastest CAGR during the forecast period due to advancements in technologies such as next-generation sequencing (NGS) and digital PCR.

Minimal Residual Disease Testing Market

Global Minimal Residual Disease Testing Market – By Technology

Based on technology, the global minimal residual disease testing market is divided into NGS, PCR, Flow Cytometry, and Fluorescence In-situ Hybridization segments. The flow cytometry segment held the highest share in the global minimal residual disease testing market in 2022, due to its high sensitivity and broad applicability. This technique involves evaluating individual cells to determine the presence of specific protein markers on their surface. A recent bone marrow sample is required for reliable results, and special antibodies are applied to the sample to identify cells with particular proteins. Depending on the flow cytometry configuration, this approach can detect a single cancer cell among 10,000 to 100,000 healthy bone marrow cells, and results can be obtained in less than a day. During the forecast period, the polymerase chain reaction (PCR) technology segment is expected to experience significant growth. The PCR method can detect cancer cells based on unique genetic anomalies, such as chromosomal alterations or mutations. PCR amplifies small DNA or RNA fragments to enhance their detectability, allowing it to identify genetic anomalies even when very few cancer cells are present. Blood cells or bone marrow samples are used for the test, and PCR can detect one cancer cell among 100,000 normal cells. However, the time required for test results to be available is typically between 5 and 14 days.

Global Minimal Residual Disease Testing Market – By Application

Based on application, the global minimal residual disease testing market is bifurcated into Hematological Malignancies and Solid Tumors segments. In 2022, the hematological malignancy cancer segment held a higher market share for MRD testing, as the use of MRD testing as a diagnostic and monitoring tool increased in these cancers. Hematological malignancies are cancers that start in blood-forming tissues or immune system cells, including leukemia, lymphoma, and multiple myeloma. The ClonoSEQ assay, which uses NGS technology, is FDA-approved for detecting and monitoring MRD in bone marrow samples from patients with multiple myeloma. The prevalence of hematological malignancies has also been on the rise. During the forecast period, the solid tumors segment is expected to witness significant growth, driven by ongoing research on the assessment of patients with solid tumors. Currently, there are no approved recommendations for using MRD testing in nonhematologic malignancies. However, the use of circulating tumor-derived DNA (ctDNA) as a prognostic biomarker for MRD after therapy for solid tumors is rapidly being incorporated into clinical trial design and translational research investigations and poised for standard clinical use. Nevertheless, the poor sensitivity of current detection methods limits their usefulness for MRD detection across a range of clinical applications, even as ctDNA detection technologies continue to evolve rapidly.

Minimal Residual Disease Testing Market Share

Global Minimal Residual Disease Testing Market – By End Use

Based on end use, the global minimal residual disease testing market is divided into Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research & Academic Institutes segments. In 2022, the hospitals segment held the highest market share in the global MRD testing market. Hospitals offer specialized expertise to help patients choose the most appropriate MRD tests. The market growth is driven by several factors, including the increasing prevalence of the target condition, the availability of multiple testing options, and the launch of new tests for better and more effective patient screening. Hospital facilities also provide better decision-making capabilities, allowing doctors and healthcare professionals to analyze patient data and provide optimal treatment options. During the forecast period, the academic and research institutes segment is expected to exhibit significant growth. This growth is associated with increasing research activities aimed at identifying candidates and establishing patient diagnoses for research participation. MRD testing for multiple myeloma is increasingly being used in clinical trials to evaluate disease response and predict the length of response. Preliminary evidence suggests that MRD positivity following treatment is associated with a higher risk of relapse, while MRD negativity results in improved progression-free survival (PFS). Furthermore, studies are being conducted to examine the relevance of sequential MRD monitoring in patients undergoing treatment.

Minimal Residual Disease Testing Market Size

Global Minimal Residual Disease Testing Market – By Region

The in-depth research report on the global minimal residual disease testing market covers country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa (MEA). North America held the highest share in the global minimal residual disease testing market due to the increasing incidence of cancer, the adoption of next-generation and polymerase chain reaction techniques, the adoption of innovative technology, and the availability of research infrastructure for proteomics, genomics, and oncology. The increasing prevalence of hematological cancers in the United States has resulted in a higher risk of residual cancerous cells, which is expected to drive demand for minimal residual disease market. The American Cancer Society has reported that 34,470 new cases of multiple myeloma and 6,660 new cases of acute lymphocytic leukemia are expected in the United States in 2022. Additionally, the Leukemia and Lymphoma Society has projected that 90,390 new lymphoma cases will be diagnosed in the United States in 2021. Furthermore, the market growth is also attributed to the increasing focus of companies on developing treatments and tests for detecting minimal residual disease.

Competitive Landscape

Major players operating in the global minimal residual disease testing market include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

  • In June 2021 - Sysmex Corporation launched a new MRD testing solution, Sysmex Inostics OncoBEAM Plus Digital PCR Kit. The solution is designed to detect and monitor low levels of MRD in patients with solid tumors.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2022

Base Year – 2022

Estimated Year – 2023

Forecast Period – 2023–2029

Facts Covered

Revenue in USD Billion

Market Coverage

North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)

Product/ Service Segmentation

Test Type, Technology, Application, End Use, Region

Key Players

Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, Thermo Fisher Scientific, Inc.

 

By Test Type

  • DNA-based Test

  • RNA-based Test

  • Immunological Test

By Technology

  • NGS

  • PCR

  • Flow Cytometry

  • Fluorescence In-Situ Hybridization

By Application

  • Hematological Malignancies

  • Solid Tumors

By End Use

  • Hospitals

  • Specialty Clinics

  • Diagnostic Laboratories

  • Research & Academic Institutes

By Region

  • North America

  • Europe

  • Asia Pacific (APAC)

  • Latin America

  • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3.  Global Minimal Residual Disease Testing Market Insights
    1. Industry Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
        2. Increasing adoption of precision medicine approaches
        3. Growing trend towards early cancer diagnosis and detection
      2. Restraints
        1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
        2. Concerns over the accuracy and reliability of MRD tests
      3. Opportunities
        1. Increasing adoption of advanced technologies, such as next-generation sequencing
        2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
      4. Challenges
        1. Need for continuous investment in research and development to stay competitive
    3. Technology Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4.  Global Minimal Residual Disease Testing Market Overview
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share and Forecast
      1. By Test Type
        1. DNA-Based Test
        2. RNA-Based Test
        3. Immunological Test
        4. Others
      2. By Technology
        1. NGS, PCR
        2. Flow Cytometry
        3. Fluorescence In-Situ Hybridization
        4. Others
      3. By Application
        1. Hematological Malignancies
        2. Solid Tumors
        3. Others
      4. By End Use
        1. Hospitals
        2. Specialty Clinics
        3. Diagnostic Laboratories
        4. Research and Academic Institutes
        5. Others
      5. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  5. North America Minimal Residual Disease Testing Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
      5. By Country
        1. United States
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        2. Canada
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
  6. Europe Minimal Residual Disease Testing Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
      5. By Country
        1. Germany
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        2. United Kingdom
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        3. Italy
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        4. France
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        5. Spain
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        6. Belgium
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        7. Russia
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        8. The Netherlands
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        9. Rest of Europe
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
  7. Asia-Pacific Minimal Residual Disease Testing Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
      5. By Country
        1. China
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        2. India
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        3. Japan
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        4. South Korea
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        5. Australia & New Zealand
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        6. Indonesia
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        7. Malaysia
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        8. Singapore
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        9. Vietnam
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        10. Rest of APAC
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
  8. Latin America Minimal Residual Disease Testing Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
      5. By Country
        1. Brazil
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        2. Mexico
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        3. Argentina
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        4. Peru
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        5. Rest of LATAM
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
  9. Middle East & Africa Minimal Residual Disease Testing Market
    1. Market Size & Forecast, 2019–2029
      1. By Value (USD Million)
    2. Market Share & Forecast
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
      5. By Country
        1. Saudi Arabia
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        2. UAE
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        3. Qatar
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        4. Kuwait
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        5. South Africa
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        6. Nigeria
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        7. Algeria
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
        8. Rest of MEA
          1. By Test Type
          2. By Technology
          3. By Application
          4. By End Use
  10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  11. Impact of Covid-19 on Global Minimal Residual Disease Testing Market
  12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Abbott Laboratories
    2. Adaptive Biotechnologies
    3. Agilent Technologies
    4. ARUP Laboratories
    5. Bio-Rad Laboratories
    6. F. Hoffmann-La Roche AG
    7. Illumina, Inc.
    8. Invivoscribe, Inc.
    9. Janssen Diagnostics LLC
    10. Luminex Corporation
    11. Myriad Genetics, Inc.
    12. Natera, Inc.
    13. QIAGEN N.V.
    14. Sysmex Corporation
    15. Thermo Fisher Scientific, Inc.
    16. Other Prominent Players
  13. Key Strategic Recommendations
  14. Research Methodology
    1.  Qualitative Research
      1.  Primary & Secondary Research
    2.  Quantitative Research
    3.  Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.  Breakdown of Primary Research Respondents, By Region
    5.  Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

List of Figures

Figure 1       Global Minimal Residual Disease Testing Segmentation

Figure 2       Global Minimal Residual Disease Testing Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2021

Figure 4       Global Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 5       Global Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 6       Global Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 7       Global Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 8       Global Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 9       Global Minimal Residual Disease Testing Market Share, By Region, By Value, 2019–2029

Figure 10     North America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 11     North America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 12     North America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 13     North America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 14     North America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 15     North America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 16     United States Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 17     United States Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 18     United States Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 19     United States Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 20     United States Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 21     Canada Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 22     Canada Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 23     Canada Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 24     Canada Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 25     Canada Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 26     Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 27     Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 28     Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 29     Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 30     Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 31     Europe Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 32     Germany Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 33     Germany Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 34     Germany Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 35     Germany Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 36     Germany Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 37     UNITED KINGDOM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 38     UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 39     UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 40     UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 41     UNITED KINGDOM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 42     Italy Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 43     Italy Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 44     Italy Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 45     Italy Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 46     Italy Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 47     France Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 48     France Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 49     France Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 50     France Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 51     France Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 52     Spain Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 53     Spain Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 54     Spain Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 55     Spain Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 56     Spain Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 57     Belgium Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 58     Belgium Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 59     Belgium Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 60     Belgium Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 61     Belgium Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 62     Russia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 63     Russia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 64     Russia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 65     Russia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 66     Russia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 67     The Netherlands Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 68     The Netherlands Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 69     The Netherlands Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 70     The Netherlands Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 71     The Netherlands Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 72     Rest of Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 73     Rest of Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 74     Rest of Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 75     Rest of Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 76     Rest of Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 77     Asia-Pacific Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 78     Asia-Pacific Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 79     Asia-Pacific Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 80     Asia-Pacific Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 81     Asia-Pacific Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 82     Asia-Pacific Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 83     China Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 84     China Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 85     China Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 86     China Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 87     China Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 88     India Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 89     India Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 90     India Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 91     India Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 92     India Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 93     Japan Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 94     Japan Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 95     Japan Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 96     Japan Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 97     Japan Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 98     South Korea Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 99     South Korea Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 100   South Korea Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 101   South Korea Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 102   South Korea Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 103   Australia & New Zealand Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 104   Australia & New Zealand Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 105   Australia & New Zealand Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 106   Australia & New Zealand Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 107   Australia & New Zealand Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 108   Indonesia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 109   Indonesia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 110   Indonesia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 111   Indonesia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 112   Indonesia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 113   Malaysia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 114   Malaysia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 115   Malaysia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 116   Malaysia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 117   Malaysia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 118   Singapore Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 119   Singapore Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 120   Singapore Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 121   Singapore Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 122   Singapore Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 123   Vietnam Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 124   Vietnam Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 125   Vietnam Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 126   Vietnam Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 127   Vietnam Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 128   Rest of APAC Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 129   Rest of APAC Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 130   Rest of APAC Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 131   Rest of APAC Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 132   Rest of APAC Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 133   Latin America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 134   Latin America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 135   Latin America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 136   Latin America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 137   Latin America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 138   Latin America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 139   Brazil Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 140   Brazil Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 141   Brazil Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 142   Brazil Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 143   Brazil Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 144   Mexico Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 145   Mexico Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 146   Mexico Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 147   Mexico Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 148   Mexico Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 149   Argentina Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 150   Argentina Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 151   Argentina Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 152   Argentina Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 153   Argentina Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 154   Peru Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 155   Peru Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 156   Peru Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 157   Peru Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 158   Peru Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 159   Rest of LATAM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 160   Rest of LATAM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 161   Rest of LATAM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 162   Rest of LATAM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 163   Rest of LATAM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 164   Middle East & Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 165   Middle East & Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 166   Middle East & Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 167   Middle East & Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 168   Middle East & Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 169   Middle East & Africa Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 170   Saudi Arabia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 171   Saudi Arabia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 172   Saudi Arabia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 173   Saudi Arabia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 174   Saudi Arabia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 175   UAE Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 176   UAE Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 177   UAE Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 178   UAE Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 179   UAE Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 180   Qatar Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 181   Qatar Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 182   Qatar Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 183   Qatar Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 184   Qatar Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 185   Kuwait Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 186   Kuwait Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 187   Kuwait Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 188   Kuwait Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 189   Kuwait Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 190   South Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 191   South Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 192   South Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 193   South Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 194   South Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 195   Nigeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 196   Nigeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 197   Nigeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 198   Nigeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 199   Nigeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 200   Algeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 201   Algeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 202   Algeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 203   Algeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 204   Algeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 205   Rest of MEA Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 206   Rest of MEA Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 207   Rest of MEA Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 208   Rest of MEA Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 209   Rest of MEA Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

 

 

List of Tables

 

Table 1 Global Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 2 Global Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 3 Global Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 4 Global Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 5 Global Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 6 Global Minimal Residual Disease Testing Market Share, By Region, By Value, 2019–2029

Table 7 North America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 8 North America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 9 North America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 10      North America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 11      North America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 12      North America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 13      United States Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 14      United States Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 15      United States Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 16      United States Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 17      United States Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 18      Canada Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 19      Canada Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 20      Canada Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 21      Canada Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 22      Canada Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 23      Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 24      Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 25      Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 26      Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 27      Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 28      Europe Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 29      Germany Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 30      Germany Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 31      Germany Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 32      Germany Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 33      Germany Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 34      UNITED KINGDOM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 35      UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 36      UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 37      UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 38      UNITED KINGDOM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 39      Italy Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 40      Italy Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 41      Italy Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 42      Italy Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 43      Italy Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 44      France Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 45      France Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 46      France Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 47      France Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 48      France Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 49      Spain Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 50      Spain Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 51      Spain Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 52      Spain Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 53      Spain Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 54      Belgium Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 55      Belgium Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 56      Belgium Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 57      Belgium Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 58      Belgium Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 59      Russia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 60      Russia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 61      Russia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 62      Russia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 63      Russia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 64      The Netherlands Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 65      The Netherlands Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 66      The Netherlands Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 67      The Netherlands Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 68      The Netherlands Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 69      Rest of Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 70      Rest of Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 71      Rest of Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 72      Rest of Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 73      Rest of Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 74      Asia-Pacific Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 75      Asia-Pacific Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 76      Asia-Pacific Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 77      Asia-Pacific Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 78      Asia-Pacific Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 79      Asia-Pacific Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 80      China Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 81      China Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 82      China Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 83      China Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 84      China Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 85      India Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 86      India Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 87      India Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 88      India Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 89      India Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 90      Japan Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 91      Japan Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 92      Japan Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 93      Japan Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 94      Japan Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 95      South Korea Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 96      South Korea Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 97      South Korea Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 98      South Korea Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 99      South Korea Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 100    Australia & New Zealand Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 101    Australia & New Zealand Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 102    Australia & New Zealand Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 103    Australia & New Zealand Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 104    Australia & New Zealand Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 105    Indonesia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 106    Indonesia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 107    Indonesia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 108    Indonesia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 109    Indonesia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 110    Malaysia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 111    Malaysia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 112    Malaysia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 113    Malaysia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 114    Malaysia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 115    Singapore Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 116    Singapore Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 117    Singapore Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 118    Singapore Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 119    Singapore Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 120    Vietnam Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 121    Vietnam Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 122    Vietnam Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 123    Vietnam Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 124    Vietnam Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 125    Rest of APAC Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 126    Rest of APAC Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 127    Rest of APAC Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 128    Rest of APAC Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 129    Rest of APAC Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 130    Latin America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 131    Latin America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 132    Latin America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 133    Latin America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 134    Latin America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 135    Latin America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 136    Brazil Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 137    Brazil Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 138    Brazil Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 139    Brazil Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 140    Brazil Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 141    Mexico Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 142    Mexico Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 143    Mexico Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 144    Mexico Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 145    Mexico Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 146    Argentina Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 147    Argentina Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 148    Argentina Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 149    Argentina Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 150    Argentina Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 151    Peru Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 152    Peru Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 153    Peru Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 154    Peru Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 155    Peru Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 156    Rest of LATAM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 157    Rest of LATAM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 158    Rest of LATAM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 159    Rest of LATAM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 160    Rest of LATAM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 161    Middle East & Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 162    Middle East & Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 163    Middle East & Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 164    Middle East & Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 165    Middle East & Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 166    Middle East & Africa Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 167    Saudi Arabia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 168    Saudi Arabia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 169    Saudi Arabia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 170    Saudi Arabia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 171    Saudi Arabia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 172    UAE Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 173    UAE Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 174    UAE Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 175    UAE Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 176    UAE Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 177    Qatar Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 178    Qatar Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 179    Qatar Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 180    Qatar Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 181    Qatar Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 182    Kuwait Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 183    Kuwait Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 184    Kuwait Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 185    Kuwait Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 186    Kuwait Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 187    South Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 188    South Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 189    South Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 190    South Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 191    South Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 192    Nigeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 193    Nigeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 194    Nigeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 195    Nigeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 196    Nigeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 197    Algeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 198    Algeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 199    Algeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 200    Algeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 201    Algeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 202    Rest of MEA Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 203    Rest of MEA Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 204    Rest of MEA Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 205    Rest of MEA Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 206    Rest of MEA Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 207    Abbott Laboratories Company Overview

Table 208    Abbott Laboratories Financial Overview

Table 209    Adaptive Biotechnologies Company Overview

Table 210    Adaptive Biotechnologies Financial Overview

Table 211    Agilent Technologies Company Overview

Table 212    Agilent Technologies Financial Overview

Table 213    ARUP Laboratories Company Overview

Table 214    ARUP Laboratories Financial Overview

Table 215    Bio-Rad Laboratories Company Overview

Table 216    Bio-Rad Laboratories Financial Overview

Table 217    F. Hoffmann-La Roche AG Company Overview

Table 218    F. Hoffmann-La Roche AG Financial Overview

Table 219    Illumina, Inc. Company Overview

Table 220    Illumina, Inc. Financial Overview

Table 221    Invivoscribe, Inc. Company Overview

Table 222    Invivoscribe, Inc. Financial Overview

Table 223    Janssen Diagnostics LLC Company Overview

Table 224    Janssen Diagnostics LLC Financial Overview

Table 225    Luminex Corporation Company Overview

Table 226    Luminex Corporation Financial Overview

Table 227    Myriad Genetics, Inc. Company Overview

Table 228    Myriad Genetics, Inc. Financial Overview

Table 229    Natera, Inc. Company Overview

Table 230    Natera, Inc. Financial Overview

Table 231    QIAGEN N.V. Company Overview

Table 232    QIAGEN N.V. Financial Overview

Table 233    Sysmex Corporation Company Overview

Table 234    Sysmex Corporation Financial Overview

Table 235    Thermo Fisher Scientific, Inc. Company Overview

Table 236    Thermo Fisher Scientific, Inc. Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Note: Please share the corporate email address for faster response

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Major factors driving the growth of Global Minimal Residual Disease Testing Market include growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests, increasing adoption of precision medicine approaches, and growing trend towards early cancer diagnosis and detection.
Ans: Global Minimal Residual Disease Testing Market size was estimated at USD 1.54 billion in 2022.
Ans: The hematological malignancies segment is expected to hold the highest market share in the Global Minimal Residual Disease Testing Market by application.
Ans: The hospitals segment is expected to hold the highest market share in the Global Minimal Residual Disease Testing Market by end user.
Ans: Key players in the Global Minimal Residual Disease Testing Market include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. 
array(1) {
  ["__ci_last_regenerate"]=>
  int(1732256758)
}